Teal is the awareness color of ovarian cancer. Women of Teal is a play on the words "Man of Steel" used to describe Superman. I have found my fellow ovarian cancer survivors to be the strongest, most helpful women in the world. They are truly Women of Teal!
This is my last post from #ASCO22. It includes a variety of Tweets dealing with studies from the meeting I found interesting.
Palliative Care
Though geared toward GU Cancers similar integrative efforts could apply to Gyn cancers too. #gyncsm#ASCO22 Slide 25 "What do Patients Want to Know?" Excellent Presentation @birensaraiyahttps://t.co/rCxSn9LQos
Larissa Meyer, MD, MPH, on an Algorithm to Find Incident Epithelial Ovarian Cancer #gyncsm algorithm will facilitate research in other claims-based data sets where cancer registry data are unavailable.https://t.co/G8sdaBn5ch
"Use of chemo is increasing while radiation therapy is decreasing" in stage II-III uterine #leiomyosarcoma. "Radiation is associated w/ improved survival in stage II and III, while there was no association between adjuvant chemo & survival in stage II." #sarcoma#gyncsmhttps://t.co/HdEkSdCZXl
— Erika Hamilton, MD (@ErikaHamilton9) June 6, 2022
Cascade Testing and ovarian cancer
Genetic testing innovation in #ovariancancer. Pilot study by Frey MK et al. found 53% success of cascade testing when clinical team directly contacted relatives for cancer family history vs. 36% when responsibility was left to patients #gyncsm#ASCO22pic.twitter.com/W7Otlu5RLG
Excited to hear Dr Jyoti Mayadev speak about “Novel Radiosensitizers in Cervical, Vaginal, and Vulvar Cancers” at #ASCO22 on ways to optimize outcomes with chemoRT for #gyncsm. Nice to see a #womenWhoCurie on stage @ASCOpic.twitter.com/qKDmsCGe7I
— Fumiko Ladd Chino, MD (@fumikochino) June 6, 2022
Thanks for joining me as I reviewed ASCO research. I hope to see you at ASCO next year.
This session was a case based discussion titled Controversies and Considerations in Adjuvant Advanced Endoemterial Cancer.
Cases were presented and questions asked of the panel which included a patient advocate, @AdrienneEcana.
#ASCO22 Endometrial Cancer session First case Women Presented late- Why? Did she not know bleeding after menopause was abnormal? Did change of guidelines ( Neg PAP, Neg HPV screen safe no need to go to gyn for 5 yrs) impact? Covid? pic.twitter.com/4S74Yk8ye0
1/2 Case 1 #ASCO22 Endometrial cancer #gyncsm When should EC patient be approached re:clinical trial? @AdrienneEcana "my goal is to destigmatize participation in a clinical trial" There is time early in treatment to offer option.
#ASCO22 Endometrial cancer #gyncsm Obesity is num 1 cause of endometrial cancer. Case 2 Not Defined menopause. Her2 testing @ajhingran Radiation important option due to lymph involvement MMR / Lynch testing should be done . Should POLE be tested? pic.twitter.com/MaFkA8b1qq
Loved watching advocate and friend @AdrienneEcana present during the Controversies & Considerations in Endometrial Cancer session at #ASCO22. So proud of this amazing advocate . Wish I could have been there in person. #gyncsmpic.twitter.com/rgkbeP2S2C
Tomorrow catch my last post from ASCO. It included varied Tweets of studies from the meeting that were not necessarily a part of the sessions I viewed.
This post will cover the Gynecologic Cancer Poster discussion session at #ASCO22 held on Saturday June 5,2022 . I recently watched this on demand.Most of the posters discussed dealt with ovarian cancer.
1)Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study. 5512
Mirvetuximab soravtansine is an antibody drug conjugate
MIRV is the first biomarker-directed therapy demonstrating anti-tumor activity in pts with FRα high Platinum-resistant OC.
2) Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial. 5513
This study also used an antibody drug conjugate.
"MORAb-202 is an antibody-drug conjugate consisting of farletuzumab (an antibody that binds to folate receptor alpha [FRα]) paired with eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin-B–cleavable linker). "
This was a Japanese expansion study and"efficacy was observed irrespective of FRα-expression levels.
slide from distillation presentation -Maroney
3)A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150. 5514
"Anetumab ravtansine (AR) is a fully-human antibody directed at the mesothelin antigen, conjugated to a tubulin polymerization inhibitor". Study was of combination AR/bevacizumab (ARB) versus weekly paclitaxel/bevacizumab (PB).
PB had better outcome than weekly ARB leading to the study termination.
Second Group of Posters: Targeted Therapies
4) IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification. 5515
5) Adavosertib in combination with carboplatin in advancedTP53-mutated platinum-resistant ovarian cancer. 5516
38% overall response rate and 76%had dose delays
"Adavosertib 225 mg BID for 2.5 days and carboplatin AUC 5 in a 21-day cycle could be safely combined and shows promising anti-tumor efficacy in patients with platinum resistant ovarian cancer. "
6)Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO)5517
"LIO-1 is assessing the oral antiangiogenic, multikinase inhibitor lucitanib in combination with the programmed cell death receptor 1 (PD-1) inhibitor nivolumab"
22% overall response rate and 46% treatment interruptions.
Third Group of Posters - Maximize remission
7) Real-world effectiveness of first-line maintenance olaparib in women withBRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study. 5518Real world results follow the SOLO-1 results. Providers asked to provide information on their patients. 36% of the population were on maintenance only 26% received PARP.
Slide from Norquist discussion
"There was prolonged benefit of 1L olaparib in newly diagnosed pts with BRCAm AOC in terms of lower likelihood of progression."
8 Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. 5519
"In final OS analyses, maintenance olaparib capsules showed consistent clinical activity in BRCAm and sBRCAm PSROC paitents. Exploratory analyses suggest similar activity in non-BRCA HRRm pts."
9)Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial. 5520
"Cytoreductive surgery for subsequent ovarian cancer relapse appears feasible and with low mortality in selected patients who received non-surgical treatment at 1st relapse despite a positive AGO-score." The AGO score isa predictor for which ovarian cancer patients can be operated on with a first recurrence.
Rare Gyn Malignancies
10)Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC) 5521
ONA-XR is a type I full progesterone antagonist that inhibits progesterone-mediated progesterone receptor activation and stabilizes progesterone receptor association with corepressors.
"ONA-XR exhibited a 12-month PFS rate of 20.1% and a CBR of 35.7% in patients with GCT ."
11)A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. 5522
"Neoadjuvant treatment with fulvestrant and abemaciclib was tolerable and demonstrated unprecedented response and CGR rates in this pilot study."
12) Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer. 5523
"Our web-based online interactive tool can help with identifying areas with high need of intervention, and inform how access, prevention and new or emerging therapies may potentially change the distribution of r/mCC disease burden"
My last ASCO Annual Meeting post will be the Clinical Science Symposium on Molecular Based Treatment of Endometrial cancer.
